Cannabinoid Encyclopedia

Health and effects

Cannabinoids and Seizure and neurodevelopmental outcomes

What studies can tell us about cannabinoids and Seizure and neurodevelopmental outcomes, including human research, early evidence, and important limits.

Updated July 2026 48 research sources Human and early research

The short answer

What does the research say about Seizure and neurodevelopmental outcomes?

Researchers have studied cannabinoids in connection with Seizure and neurodevelopmental outcomes. The current literature covers CBD and CBDV. This page brings together 14 human-study sources, 28 research reviews, and 6 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. There is no single answer that applies to every cannabinoid, dose, product, or person. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Seizure and neurodevelopmental outcomes.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Seizure and neurodevelopmental outcomes covers CBD and CBDV; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Seizure and neurodevelopmental outcomes

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human and early-stage research

CBD

Researchers have studied CBD in connection with Seizure and neurodevelopmental outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 2

Human and early-stage research

CBDV

Researchers have studied CBDV in connection with Seizure and neurodevelopmental outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 3

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

14 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

28 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

6 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on Seizure and neurodevelopmental outcomes is not one kind of study. This source set includes 21 narrative or expert reviews, 10 clinical studies in people, 7 systematic reviews or meta-analyses, and 4 animal studies. 3

The recorded populations or models include people or patients (23 sources), pediatric, adolescent, or developmental context (15 sources), and animal models (3 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is seizure-related outcomes (27 sources) and seizure-related or neurodevelopmental outcomes (21 sources). Closely related outcome names can still describe different measurements. 5

The Seizure and neurodevelopmental outcomes source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.

On this page, this source examines CBD and seizure and neurodevelopmental outcomes. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
seizure-related outcomes
Evidence stage
evidence still limited

systematic review or meta-analysis

Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.

On this page, this source examines CBD and seizure and neurodevelopmental outcomes. 2

Study type
systematic review or meta-analysis
Population or model
pediatric, adolescent, or developmental context
Outcome focus
seizure-related outcomes
Evidence stage
evidence still limited

narrative or expert review

Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.

On this page, this source examines CBDV and seizure and neurodevelopmental outcomes. 3

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
seizure-related or neurodevelopmental outcomes
Evidence stage
evidence still limited

systematic review or meta-analysis

Anti-seizure medications for Lennox-Gastaut syndrome.

On this page, this source examines CBD and seizure and neurodevelopmental outcomes. 4

Study type
systematic review or meta-analysis
Population or model
pediatric, adolescent, or developmental context
Outcome focus
seizure-related outcomes
Evidence stage
evidence still limited

systematic review or meta-analysis

Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.

On this page, this source examines CBD and seizure and neurodevelopmental outcomes. 5

Study type
systematic review or meta-analysis
Population or model
people or patients
Outcome focus
seizure-related outcomes
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on Seizure and neurodevelopmental outcomes should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Can cannabinoids help with Seizure and neurodevelopmental outcomes?

Research exists, but there is not one answer for every cannabinoid or product. The source set includes human research as well as earlier-stage studies. 7

Why can studies reach different answers?

Studies may test different cannabinoids, doses, formulations, routes, people, and outcomes. Those differences can change the result. 8

What should I check in a study?

Check whether it studied people, what product and dose it used, what it measured, how long it lasted, and whether safety was reported. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. narrative or expert review; evidence still limited PubMed 39854828 DOI 10.1016/j.yebeh.2024.110261
  2. 2
    Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. systematic review or meta-analysis; evidence still limited PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
  3. 3
    Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. narrative or expert review; evidence still limited PubMed 33895189 DOI 10.1016/j.pharmthera.2021.107878
  4. 4
    Anti-seizure medications for Lennox-Gastaut syndrome. systematic review or meta-analysis; evidence still limited PubMed 33825230 DOI 10.1002/14651858.cd003277.pub4
  5. 5
    Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. systematic review or meta-analysis; evidence still limited PubMed 38427284 DOI 10.1002/epi4.12923
  6. 6
    Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. systematic review or meta-analysis; evidence still limited PubMed 33754312 DOI 10.1007/s40263-021-00807-y
  7. 7
    Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. systematic review or meta-analysis; evidence still limited PubMed 37695433 DOI 10.1007/s40265-023-01936-y
  8. 8
    Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. systematic review or meta-analysis; evidence still limited PubMed 39541799 DOI 10.1016/j.euroneuro.2024.10.006
  9. 9
    Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. systematic review or meta-analysis; evidence still limited PubMed 36417631 DOI 10.1590/1806-9282.2022d689
  10. 10
    Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. clinical study in people; human research PubMed 33346789 DOI 10.1001/jamaneurol.2020.4607
  11. 11
    Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. clinical study in people; human research PubMed 29395273 DOI 10.1016/s0140-6736(18
  12. 12
    Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. clinical study in people; human research PubMed 26724101 DOI 10.1016/s1474-4422(15
See all 48 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. narrative or expert review; evidence still limited / 1 linked research note PubMed 33895189
  2. Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. narrative or expert review; evidence still limited / 1 linked research note PubMed 32335286
  3. Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. narrative or expert review; evidence still limited / 1 linked research note PubMed 32825313
  4. Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 42339654
  5. Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? narrative or expert review; evidence still limited / 1 linked research note PubMed 33613289
  6. Investigational cannabinoids in seizure disorders, what have we learned thus far? narrative or expert review; evidence still limited / 1 linked research note PubMed 29842819
  7. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. clinical study in people; preclinical research / 1 linked research note PubMed 35364618
  8. Phytocannabinoids and epilepsy. narrative or expert review; evidence still limited / 1 linked research note PubMed 25475762
  9. Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. preclinical research / 1 linked research note PubMed 24282673
  10. Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin. preclinical research / 1 linked research note PubMed 29588939
  11. Antiepileptic Drugs in Clinical Development: Differentiate or Die? narrative or expert review; evidence still limited / 1 linked research note PubMed 28799516
  12. The potential role of cannabinoids in epilepsy treatment. narrative or expert review; evidence still limited / 1 linked research note PubMed 28845714
  13. Preclinical safety and efficacy of cannabidivarin for early life seizures. animal study; preclinical research / 1 linked research note PubMed 30633929
  14. Cannabinoids for epilepsy: What do we know and where do we go? narrative or expert review; evidence still limited / 1 linked research note PubMed 29214639
  15. Cannabidivarin is anticonvulsant in mouse and rat. animal study; mechanism-focused research / 1 linked research note PubMed 22970845
  16. Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. animal study; mechanism-focused research / 1 linked research note PubMed 31447649
  17. Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. clinical study in people; human research / 1 linked research note PubMed 34210360
  18. Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36583706
  19. Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. clinical study in people; human research / 1 linked research note PubMed 31748505
  20. Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 39541799
  21. The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia. animal study; preclinical research / 1 linked research note PubMed 41159452
  22. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 36206805
  23. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. narrative or expert review; evidence still limited / 1 linked research note PubMed 39007525
  24. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. clinical study in people; human research / 1 linked research note PubMed 33346789
  25. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33754312
  26. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 33332006
  27. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 36417631
  28. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. narrative or expert review; evidence still limited / 1 linked research note PubMed 36194365
  29. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex. human research / 1 linked research note PubMed 37769547
  30. Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex. human research / 1 linked research note PubMed 40650804
  31. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. mechanism-focused research / 1 linked research note PubMed 39008349
  32. CBD in the Treatment of Epilepsy. narrative or expert review; evidence still limited / 1 linked research note PubMed 38731471
  33. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies. narrative or expert review; evidence still limited / 1 linked research note PubMed 37655228
  34. Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. narrative or expert review; evidence still limited / 1 linked research note PubMed 39854828
  35. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. clinical study in people; human research / 1 linked research note PubMed 26724101
  36. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. clinical study in people; human research / 1 linked research note PubMed 29395273
  37. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 38427284
  38. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. clinical study in people; human research / 1 linked research note PubMed 29768152
  39. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. clinical study in people; human research / 1 linked research note PubMed 28538134
  40. State-of-the-art management of Dravet syndrome. narrative or expert review; evidence still limited / 1 linked research note PubMed 40836583
  41. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. clinical study in people; mechanism-focused research / 1 linked research note PubMed 29540584
  42. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 37695433
  43. Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. clinical study in people; evidence still limited / 1 linked research note PubMed 40072476
  44. Treatment of Dravet Syndrome. narrative or expert review; evidence still limited / 1 linked research note PubMed 27264138
  45. Current and emerging pharmacotherapies in Lennox-Gastaut syndrome. narrative or expert review; evidence still limited / 1 linked research note PubMed 40468679
  46. Anti-seizure medications for Lennox-Gastaut syndrome. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33825230
  47. Lennox-Gastaut syndrome: New treatments and treatments under investigation. narrative or expert review; evidence still limited / 1 linked research note PubMed 32409177
  48. Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review. narrative or expert review; evidence still limited / 1 linked research note PubMed 33243685